Prasinezumab

DB14788Investigational

Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).

Mechanism: Pharmacologically active on Alpha-synuclein
Curator reviewed
Code names: PRX002 · RO7046015

Resolves to

Compound

UNIIP3Z0Z3P1ZICAS1960462-19-4

Targets

P37840SNCA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Prasinezumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account